Tinzaparin

{{DrugProjectFormSinglePage |authorTag=Alejandro Lemor, M.D. [1] |genericName=Tinzaparin sodium |aOrAn=a |drugClass=[[low molecular weight heparin |indicationType=treatment |indication=acute symptomatic deep vein thrombosis with or without pulmonary embolism |hasBlackBoxWarning=Yes |adverseReactions=bleeding, erythema, increase liver function tests, neurologic pain |blackBoxWarningTitle=SPINAL/EPIDURAL HEMATOMAS |blackBoxWarningBody=Spinal/Epidural Hematomas: Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

• Use of indwelling epidural catheters
• Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants.
• A history of traumatic or repeated epidural or spinal punctures
• A history of spinal deformity or spinal surgery

Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.

Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis |offLabelAdultGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Tinzaparin in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Tinzaparin in adult patients. |offLabelPedGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Tinzaparin in pediatric patients. |offLabelPedNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Tinzaparin in pediatric patients. |alcohol=Alcohol-Tinzaparin interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. }}

Tinzaparin

Clinical data
ATC code	B01AB10 (WHO)
Identifiers
CAS Number	9041-08-1
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}

WikiDoc Resources for Tinzaparin
Articles
Most recent articles on Tinzaparin Most cited articles on Tinzaparin Review articles on Tinzaparin Articles on Tinzaparin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Tinzaparin Images of Tinzaparin Photos of Tinzaparin Podcasts & MP3s on Tinzaparin Videos on Tinzaparin
Evidence Based Medicine
Cochrane Collaboration on Tinzaparin Bandolier on Tinzaparin TRIP on Tinzaparin
Clinical Trials
Ongoing Trials on Tinzaparin at Clinical Trials.gov Trial results on Tinzaparin Clinical Trials on Tinzaparin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Tinzaparin NICE Guidance on Tinzaparin NHS PRODIGY Guidance FDA on Tinzaparin CDC on Tinzaparin
Books
Books on Tinzaparin
News
Tinzaparin in the news Be alerted to news on Tinzaparin News trends on Tinzaparin
Commentary
Blogs on Tinzaparin
Definitions
Definitions of Tinzaparin
Patient Resources / Community
Patient resources on Tinzaparin Discussion groups on Tinzaparin Patient Handouts on Tinzaparin Directions to Hospitals Treating Tinzaparin Risk calculators and risk factors for Tinzaparin
Healthcare Provider Resources
Symptoms of Tinzaparin Causes & Risk Factors for Tinzaparin Diagnostic studies for Tinzaparin Treatment of Tinzaparin
Continuing Medical Education (CME)
CME Programs on Tinzaparin
International
Tinzaparin en Espanol Tinzaparin en Francais
Business
Tinzaparin in the Marketplace Patents on Tinzaparin
Experimental / Informatics
List of terms related to Tinzaparin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]